Collectively, these findings indicate that Hsp90 inhibition enhances tumor antigen presentation through multiple mechanisms, including transcriptional induction of differentiation antigens, degradation of client proteins, and proteasome-driven broadening of the antigenic repertoire. This evidence concerns the gene HSP90AA1 and neoplasm.